The FDA has cleared its first automated insulin pump for adults with Type 2 diabetes, with Insulet’s Omnipod 5 delivery system opening the door to a population of more than 6 million people.

Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

After collecting FDA green lights for 90- and 180-day versions, the agency has cleared the latest generation of the Eversense ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

you may want to ask your doctor about the insulin pump. Insulin pumps are small, computerized devices (about the size of a small cell phone) that allow for a continuous flow of rapid-acting ...

Aug. 26 (UPI) --The Food and Drug Administration on Monday approved Insulet's Omnipod 5 automated insulin delivery system for people with Type 2 diabetes. In 2022, the FDA signed off on the system ...

Continuous blood glucose monitors, which are inserted just under the skin, or implanted in the body, can connect to smartphones, or to insulin pumps, avoiding the need for people to do regular ...

Diabetics who fly with an insulin pump could find themselves with lower-than-normal blood sugar levels, a new study sa ...

Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...

Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetesWith a single sensor, the ...